Evidence map›Paper›PMID 42488645›Full record

ReviewFrontiers in immunology2026

Enhancing CAR-NK persistence to unlock its full therapeutic potentials.

Ovini Amarasinghe, Heqing Ma, Cédric S Tremblay, Sam K P Kung

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Ovini AmarasingheDepartment of Immunology, Max Rady College of Medicine, Rady Faculty of Health Sciences, University of Manitoba, Winnipeg, MB, Canada.
Heqing MaDepartment of Immunology, Max Rady College of Medicine, Rady Faculty of Health Sciences, University of Manitoba, Winnipeg, MB, Canada.
Cédric S TremblayDepartment of Immunology, Max Rady College of Medicine, Rady Faculty of Health Sciences, University of Manitoba, Winnipeg, MB, Canada.
Sam K P KungDepartment of Immunology, Max Rady College of Medicine, Rady Faculty of Health Sciences, University of Manitoba, Winnipeg, MB, Canada.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Chimeric Antigen Receptor-Natural Killer Cell (CAR-NK) is a promising next-generation immunotherapy. Persistence of CAR-NK cell therapy is considered a key hurdle limiting its full therapeutic potential. This review highlighted the causes of poor CAR-NK persistence and summarized strategies developed to improve CAR-NK persistence in both hematologic malignancies and solid tumors. These strategies included cytokine and cytokine signaling mediated strategies; optimization of NK cell source and CAR design; intrinsic and extrinsic checkpoint disruption and metabolic reprogramming; and lymphodepletion, alloevasion and fratricide evasion strategies. Multiple strategies that aim at improving

Indexed as

Immunotherapy, AdoptiveKiller Cells, NaturalNeoplasmsReceptors, Chimeric AntigenAnimalsCytokinesHumansCytokinesReceptors, Chimeric AntigenCARgenetic engineeringNKpersistencetumor immunotherapy

Identifiers

PMID42488645
PMCPMC13388905

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.